Ocugen (MEX:OCGN) Receivables Turnover : 0.00 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Ocugen Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ocugen's Revenue for the three months ended in Mar. 2025 was MXN30.30 Mil. Ocugen's average Accounts Receivable for the three months ended in Mar. 2025 was MXN0.00 Mil.

Ocugen Receivables Turnover Historical Data

The historical data trend for Ocugen's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Receivables Turnover Chart

Ocugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

Ocugen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ocugen's Receivables Turnover

For the Biotechnology subindustry, Ocugen's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Ocugen's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Ocugen Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Ocugen's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	84.57	/ (	(0	+	0)	/	1 )
=	84.57	/	0
=	N/A

Ocugen's Receivables Turnover for the quarter that ended in Mar. 2025 is calculated as

	Receivables Turnover (Q: Mar. 2025 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2025 )	/ (	(Accounts Receivable (Q: Dec. 2024 )	+	Accounts Receivable (Q: Mar. 2025 ))	/	count )
=	30.299	/ (	(0	+	0)	/	1 )
=	30.299	/	0
=	N/A

Ocugen (MEX:OCGN) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Ocugen Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Ocugen's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

OCGN:USA 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").